Skip to main content

Research Repository

Advanced Search

Efficacy of intravitreal bevacizumab on diabetic macular oedema in an African population

Kyei, Samuel; Asare, Frederick Afum; Assan, John Kwesi; Zaabaar, Ebenezer; Assiamah, Frank; Obeng, Eric Obour; Asiedu, Kofi

Efficacy of intravitreal bevacizumab on diabetic macular oedema in an African population Thumbnail


Authors

Samuel Kyei

Frederick Afum Asare

John Kwesi Assan

Ebenezer Zaabaar

Frank Assiamah

Eric Obour Obeng

Kofi Asiedu



Abstract

Purpose
To evaluate the short-term effect of intravitreal bevacizumab (avastin) injection on visual outcomes of patients with diabetic macular oedema.

Methods
A retrospective cross-sectional study was conducted to evaluate 39 eyes of thirty-nine patients (mean age ± SD: 61.4 ± 15.0 years) that received intravitreal bevacizumab injection (1.25 mg in 0.05 ml) as treatment for diabetic macular oedema between January 2014 and July 2019 in Ghana. Data on visual acuity and central macular thickness before treatment and 6 weeks post-treatment were collected and analysed using paired t-test. Ordinary least squares linear regression analysis was also conducted to determine the relationship between improvement in visual acuity and central macular thickness after treatment and other predictor variables.

Results
The mean ± SD visual acuity (LogMAR-equivalent of Snellen) of patients with diabetic macular oedema significantly improved from 0.84 ± 0.58 LogMAR before treatment to 0.69 ± 0.58 LogMAR at 6 weeks post-treatment (mean difference: 0.15 ± 0.32 LogMAR; 95% CI: 0.04 to 0.25; p = 0.01). Mean macular thickness ± SD on the other hand, reduced significantly (p < 0.001) from 316.54 ± 75.35 μm before treatment to 275.54 ± 57.43 μm after treatment. While age and worse pre-treatment visual acuity predicted improvement in visual acuity after treatment, a higher central macular thickness before treatment predicted an improvement in central macular thickness after intravitreal bevacizumab injection.

Conclusion
Treatment with intravitreal bevacizumab injection produces short-term improvement in vision and reduction in central macular thickness in African patients with diabetic macular oedema.

Journal Article Type Article
Acceptance Date Mar 19, 2023
Online Publication Date Mar 29, 2023
Publication Date 2023-12
Deposit Date Oct 10, 2024
Publicly Available Date Oct 11, 2024
Journal Irish Journal of Medical Science (1971 -)
Print ISSN 0021-1265
Electronic ISSN 1863-4362
Publisher Springer Verlag
Peer Reviewed Peer Reviewed
Volume 192
Issue 6
Pages 2777-2783
DOI https://doi.org/10.1007/s11845-023-03348-z
Public URL https://uwe-repository.worktribe.com/output/13278637

Files





You might also like



Downloadable Citations